Stifel initiated coverage of OptimizeRx with a rating of Buy and set a new price target of $19.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $7.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 12/20/2024 | $5.50 | Equal-Weight | Stephens |
| 7/25/2024 | $18.50 | Buy | B. Riley Securities |
| 4/4/2024 | $15.00 | Mkt Outperform | JMP Securities |
| 1/3/2024 | $15.00 | Equal Weight | Barclays |
| 2/2/2023 | $30.00 | Buy | B. Riley Securities |
| 11/1/2022 | $19.00 | Buy | Stifel |
| 7/15/2022 | $38.00 | Outperform | SVB Leerink |
8-K - OptimizeRx Corp (0001448431) (Filer)
SCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)
4 - OptimizeRx Corp (0001448431) (Issuer)
4/A - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board of Directors. Varghese Presti brings more than 25 years of experience at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate innovation into real-world
- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously
Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50
B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50
4 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
- Q4 revenue of $32.2 million- Q4 gross profit increased 9% year-over-year to $24.1 million- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million- Paid off an incremental $2 million in principal from term loan during Q4- OptimizeRx's Board authorizes a $10 million share repurchase program WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, March 5, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific T
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board of Directors. Varghese Presti brings more than 25 years of experience at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate innovation into real-world
Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (NASDAQ:LAMR), one of the largest out-of-home (OOH) advertising companies in North America, today announced a strategic partnership to revolutionize OOH advertising for pharmaceutical and healthcare brands. Through this collaboration, OptimizeRx's
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
SC 13G - OptimizeRx Corp (0001448431) (Subject)
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)